ESR1 and diabetes mellitus: In addition, breast cancer patients with diabetes were more likely to have larger tumor size, later pathological stages, a higher rate of lymph node metastasis, and a higher rate of ER-negative expression, which was also consistent with the findings of Hou et al. [25].